Lentiviral vectors (LV) have been used for the delivery of genes into hematopoietic stem and progenitor cells (HSPC) in clinical trials worldwide. LV, in contrast to retroviral vectors, have not been associated with insertion site-associated malignant clonal expansions, and thus have been considered safer. Here, however, we present a case of markedly abnormal dysplastic clonal hematopoiesis impacting the erythroid, myeloid and megakaryocytic lineages in a rhesus macaque transplanted with HSPCs that were transduced with a LV containing a strong retroviral murine stem cell virus (MSCV) constitutive promoter-enhancer in the LTR. 9 insertions were mapped in the abnormal clone, resulting in overexpression and aberrant splicing of several genes of interest, including the cytokine stem cell factor and the transcription factor PLAG1. This case represents the first clear link between a lentiviral insertion-induced clonal expansion and a clinically abnormal transformed phenotype following transduction of normal primate or human HSPC, and are thus concerning, and suggest that strong constitutive promoters should not be included within LV vectors.
Introduction
Lentiviral vectors(LV) have been successfully used for the delivery of genetic material into hematopoietic stem and progenitor cells(HSPCs) in clinical trials for inherited non-malignant diseases [1] [2] [3] [4] [5] [6] [7] [8] . In contrast to γ-retroviral vectors, which have shown to induce insertion-associated leukemias both in clinical trials 9 and in non-human primate models 10 , LV have not been associated with malignant clonal expansions in clinical trials or large animal models 11 . LVs integrate preferentially within active genes rather than near transcriptional start sites 12, 13 , and have thus been considered less likely to activate nearby proto-oncogenes. However, reports from recent clinical trials suggest that LVs are capable of inducing insertion-site associated clonal (albeit, non-malignant) expansions 8, 14 . Long-term monitoring of transduced HSPC clones in human and nonhuman primates remains critical for assessing the safety of LV gene therapies.
Our laboratory has used a rhesus macaque (RM) genetic barcoding model to study the output of lentivirally-transduced transplanted HSPC at a clonal level over time [15] [16] [17] [18] ; such a setting closely resembles that of lentiviral HSPC gene therapy trials in which autologous HSPC are collected, transduced, and reinfused into the patient. In our published and unpublished studies, we have tracked over 101,000 individual lentiviral vector insertions in 9 transplanted macaques followed for up to six years and observed no clonal expansions associated with a transformed or aberrant hematologic phenotype.
We now report on the development of aberrant, markedly dysplastic fatal clonal hematopoiesis in one animal, impacting the erythroid, myeloid and megakaryocytic lineages and originating from a single transduced HSPC clone containing 9 integrated LVs.
Methods (See Supplemental Methods for additional details)

Autologous transplantation of lentivirally-barcoded HSPC
CD34 + HSPC were collected from ZL34, a 4-year old male rhesus macaque, following mobilization with G-CSF/AMD1300, transduced(MOI=25) with a barcoded lentivirus library, and reinfused into the macaque following TBI as described [15] [16] [17] [18] . ZL34 received weekly dosing with 5mg/kg cidofovir to suppress CMV reactivation.
Barcode retrieval
DNA was extracted using the DNeasy Blood & Tissue Kit(Qiagen). 200ng was used for barcode retrieval PCR with Phusion High-Fidelity DNA Polymerase(ThermoFisher) via 28 cycles of 98°C-10 seconds, 70°C-30 seconds, 72°C-30 seconds; then 72°C-10 minutes. Indexed or non-indexed forward primers and indexed reverse primers were added (Table S6 ) for multiplex sequencing. Following gel purification, 15-24 multiplexed samples were used to create a DNA library for sequencing on an Illumina HiSeq2500/3000. Custom Python code(https://github.com/d93espinoza/barcode_extracter) was used for extraction and processing of barcodes from FASTQ files as described [15] [16] [17] [18] . For modified barcode recovery, "Starcode" software(https://github.com/gui11aume/starcode) was used for extraction and processing of barcodes. Visualization was performed using custom R code. For original data, contact dunbarc@nhlbi.nih.gov.
Results
Lentiviral transduction and transplantation
We developed a lentiviral barcoding model to quantitatively study the output of thousands of individual HSPC following autologous transplantation [15] [16] [17] [18] . As part of our ongoing studies, we transplanted animal ZL34 with autologous CD34 + HSPC transduced with a lentiviral barcoding vector driving GFP expression via the strong murine retroviral MSCV promoter-enhancer inserted within the lentiviral long terminal repeat(LTR)( Figure 1A ). The transduction/transplantation protocols utilized were unchanged from our prior experience [15] [16] [17] [18] and the multiplicity of infection(MOI), CD34 + transplanted dose(cells/kg), and GFP% of the infused cells were within the ranges utilized for prior animals(Table S1, n = 10). ZL34, along with another monkey, ZL40 (Table S1) , received CMV-suppressing cidofovir for 4 months to study the impact of CMV reactivation on immune reconstitution. With the exception of ZL34, all other animals, including ZL40 also receiving cidofovir on the same schedule, continue to show stable, highly polyclonal output from transduced HSPC with no evidence for genotoxicity or malignant clonal expansions at latest follow up(4 months -70 months, median: 25 months), regardless of having received HSPC transduced with vectors containing either an internal EF1α promoter(n=3) or the LTR-embedded MSCV promoter(n= 7), as previously published [15] [16] [17] .
Development of abnormal hematopoiesis
ZL34 engrafted normally post-transplantation as compared to other animals, promptly recovering neutrophils to greater than 500/uL, platelets to >200,000 platelets/uL, and hemoglobin to >9 g/dL( Figures 1B; S1A, B ). However, ZL34's platelet count declined beginning 49 days post-transplantation to levels far below the range maintained in other transplanted macaques( Figure 1B) , requiring platelet transfusions to treat bleeding. Waxing and waning eosinophilia, without identified infectious, drug or allergic etiology, emerged 50 days post-transplantation and became persistent by day 300( Figure 1B ). Eosinophilia has not developed in other macaques on the same transplant regimen. The morphology of neutrophils became markedly dysplastic, with hypogranulartiy and bilobulated/hypolobulated nuclei, despite normal neutrophil counts and lack of circulating blasts( Figures 1C; S1A ). Monocytes and basophils also rose to well above normal range by day 300 (Figures 1B; S1C ). In contrast, lymphocyte counts remained within expected post-transplant ranges( Figure S1D ). Figure 1D ).
Compared to healthy transplanted(ZL40 and ZK22) and non-transplanted(ZL08) RMs, ZL34's BM at day 424 was hypercellular with increased eosinophils and a marked erythroid dominance, and markedly dysplastic uninuclear micro-megakaryocytes( Figure   1E ). Blasts were not increased. Day 543 BM karyotype was normal in 20/20 metaphases. Splenic red pulp was markedly expanded due to extramedullary hematopoiesis, with infiltration of immature CD71 + erythroid cells( Figure 1F [15] [16] [17] [18] (Figure 1G , S1F). In contrast, %GFP + granulocytes(including neutrophils and eosinophils) and monocytes approached 100%, coincident with development of markedly abnormal blood counts, suggesting expansion of transduced cells within these lineages. %GFP expression in the circulating nRBCs was also very high, but dropped precipitously before euthanasia, potentially due to transgene silencing. Other barcoded animals did not show expansion of GFP+ cells of any lineage over time, with similar levels in all lineages other than delayed reconstitution of GFP+ T cells due to TBI effects on the thymus( Figure S1F and [15] [16] [17] ).
The %GFP + of CD34 + BM HSPC also increased over time, reaching over 90%.
Flow cytometric analysis of CD34 + subsets based on prior validation in macaques 20 , showed that the most primitive CD34 + CD90 + CD45RApopulation, highly-enriched for multipotent long-lived HSCs, was most markedly GFP + , with lower percentages in the CD34 + CD90 -CD45RA + population, containing lymphoid precursors 20 (Figure S2A-C). Of note, the CD34 + CD90 + CD45RApopulation was also markedly-expanded in ZL34 BM compared to normal, and present in the spleen, suggesting a differentiation block as well as extramedullary hematopoiesis (Figure S2A, B) . These findings are consistent with development of an MPN/MDS neoplastic syndrome resulting from abnormalities of transduced primitive HSPC.
A single expanded transduced clone was responsible for abnormal hematopoiesis
We performed quantitative barcode retrieval from T cells, B cells, neutrophils, eosinophils, monocytes, nRBCs and CD34+ cells using primers flanking the barcode region [15] [16] [17] [18] (Figure 2A -G). 6 barcodes contributed equally and accounted for 100% of barcodes from nRBCs at all time points. The same 6 clones appeared and expanded in neutrophils and monocytes beginning at day 187, replacing earlier highly polyclonal contributions. Eosinophils at day 494 contained only the same 6 dominant barcodes. In contrast, T and B cells maintained polyclonal diversity over time, with intermittent detection of much lower levels of the 6 barcodes, likely due to contamination with clonally-expanded myeloid or erythroid cells during sorting, and/or aberrant marker expression on dysplastic myeloid cells. Using this strategy, we recovered an additional 2 barcodes from circulating nRBCs, for a total of 9( Figure S3 ).
Because these expanded barcodes contributed roughly equally to every sample, we suspected multiple vector insertions within a single originating clonal HPSC. We plated ZL34 and control BM CD34 + cells in semi-solid media allowing barcode retrieval from individual colony-forming units (CFU). Of note, despite the erythroid predominance in the BM, a reduced ratio of erythroid/myeloid colonies was observed in ZL34 compared to normal BM( Figure S4 ). We plucked individual GFP+ myeloid CFU. All 9 barcodes were retrieved together from the majority of individual CFU( Figure 2H ). Rare CFU lacked the 9 barcodes of interest but each instead contained 1-4 other barcodes.
Vector copy number (VCN) in samples from ZL34 and other lentivirally-barcoded
RMs was determined by quantitative PCR. The normalized VCN per GFP + cell for nRBCs, eosinophils, monocytes, neutrophils and CD34 + HSPC from late time points in ZL34 averaged 8.5 copies/cell ( Figure 2I ) which along with the CFU barcode analysis supports a conclusion that expansion from a single HSPC clone with 9 vector insertions was responsible for the myelodysplastic/myeloproliferative neoplasm in ZL34. The uninvolved B and T cells lineages in ZL34 had much lower VCN per GFP + cell, as did myeloid and lymphoid lineages in other barcoded macaques( Figure 2I ).
Retrieval of LV insertion sites for the 9 dominant barcodes.
We recovered 9 LV insertions from circulating nRBCs using standard methodologies( Figure 3A ; Table S2 ). In contrast, insertions retrieved from neutrophils at day 96 were polyclonal (Table S2 ). We were able to link each of the 9 dominant barcodes to one of the 9 nRBC insertions via PCR amplification and sequencing( Figure   3A ). 4 insertions localized to introns within the NCAM2, EIF3E, PLAG1, and IMMP2L genes, with PLAG1, NCAM2 and EIF3E proviral insertions in the same orientation as endogenous transcripts, and the IMMP2L insertion in the opposite orientation. A number of additional genes were located within 1 Mb windows surrounding each of the 9 insertions(Figures 3B;S5). One insertion was less than 20 kb downstream of KITLG, encoding stem cell factor(SCF), a cytokine of importance in hematopoiesis. None of the insertions localized to known CTCF binding sites, or rhesus macaque sequences homologous to open chromatin regions mapped in human hematopoietic cells( Figure   S6 ).
Impact of insertions on gene expression.
We performed bulk RNA-seq on ZL34 PB nRBCs, BM nRBCs, and BM CD34 + HSPCs obtained on days 424-553 post-transplant, as well as on control RM BM nRBCs and BM CD34 + HSPCs. No control RM PB nRBCs were obtained, since nRBCs are not found in normal PB. We asked whether expression of genes interrupted by or within 1Mb of any of the 9 insertions(Figures S5,S7) were differentially-expressed in ZL34 compared to controls. We found 5 genes within these windows to be significantly differentially expressed combining nRBC and CD34 data, regressing out the source(PB or BM) and cell type(HSPC or nRBC) such that only significant differences attributed to condition(ZL34 cells vs controls) were identified(log2 fold change > 1 or < -1, and adjusted p-value < 0.01)( Figure 3C -D). NCAM2 and PLAG1 with intronic insertions in the same orientation were overexpressed, KITLG with an insertion 24kB downstream was overexpressed, ISOC1 with an insertion 18kB upstream was overexpressed, and TES with an insertion 250kB upstream was under-expressed. When restricting analysis to nRBCs, 4 genes were differentially expressed: NCAM2, PLAG1, KITLG, and ISOC1( Figure S8A-B ).
When considering all recovered transcripts whether adjacent to insertions or not, a number of additional genes were differentially expressed. KITLG, NCAM2, and PLAG1 were among the top 100 in combined HSPC and nRBC analysis( Figure 3E ; Table S3 ) and were either within the top 100 or differentially expressed within nRBCs alone( Figure S8C ; Table S3 ). As expected from the hemoglobin analysis( Figure 1D ), HBG2 transcripts, encoding the g-globin chain, were significantly upregulated in ZL34 nRBCs( Figure S8C ). SCF binds to the c-kit tyrosine kinase receptor on HSPC and stimulates survival and proliferation 21, 22 . SCF is normally produced by BM stromal elements, not HSPC. We measured soluble SCF levels in ZL34 and control blood and in media conditioned by cultured ZL34 and normal PB MNC( Figure 4A ). The secreted isoform of SCF was not detected above background in cultured samples. An increase in SCF was detected in ZL34 serum. Using an antibody that reacts with the transmembrane isoform of SCF, we found clear increased expression of cell-associated SCF in hematopoietic cells as shown by immunohistochemistry on marrow sections, and via FACS(
PLAG1 is a zinc finger transcription factor and proto-oncogene upregulated in salivary gland tumors 23 and in murine and human myeloid leukemias 24, 25 . At the protein level, PLAG1 was overexpressed on a per cell basis in ZL34 CD45 -nRBCs, HSPCs, and monocytes but not T or B cells, as shown via intracellular FACS and most strikingly immunohistochemistry, revealing numerous intensely PLAG1-positive BM cells compared to controls( Figure 4B ,C; S9B). Increased activity of PLAG1 was confirmed by significant increases in expression of known downstream targets, including IGF2, which encodes insulin-like growth factor 2(p=3.66 * 10 -17 ) and DLK1 (p=7.70 * 10 -31 ), both imprinted genes reported to be dysregulated in PLAG1 associated tumors 26-29 ( Figure   4D ). MSI2, a gene under direct regulation by PLAG1 30 and whose product Musashi-2 is reported to promote HSPC expansion 31 and self-renewal was also upregulated(p=5.37 * 10 -5 )( Figure 4D ). Of note, mRNA encoding HMGA2, a transcription factor functionally upstream of PLAG1 32 , was expressed at a lower level in ZL34 nRBCs and HSPCs compared to control samples. Insertional overexpression of HMGA2 has been previously-linked to clonal expansion in a lentiviral gene therapy clinical trial 8 , suggesting HMGA2 may stimulate HSPC clonal expansion via its impact on PLAG1 expression and activation of downstream targets active on HSPC such as MSI2, and that tonic low level HMGA2 expression may be involved in normal HSPC homeostasis, controlled by feedback from downstream targets.
NCAM2 is an adhesion molecule required for cell-cell or cell-matrix interactions during nervous system development, but is not normally expressed in hematopoietic cells, and dysregulation has not been linked to hematologic disease. Both FACS and immunohistochemistry confirmed overexpression of NCAM2 at a protein level in CD34 + cells, nRBC, and monocytes( Figure 4B ,C; S9B). Decreased expression of the tumor suppressor TES has not been previously linked to hematologic malignancies. The TES gene itself was not directly disrupted by an insertion, thus downregulation of this gene must have been indirect, via disruption of a regulatory element. There is little information about the gene product of ISOC1. It is not expressed in hematopoietic cells and has no known link to hematologic disease.
Insertion-related aberrant splicing.
LV vectors have been reported to disrupt splicing via formation of hybrid vectorgene transcripts expressed from viral promoters, resulting in dysregulated expression, alterations in isoform, and/or loss of transcript regulatory sequences 33,34 . We first interrogated RNA-seq data for any differentially-spliced genes and found that ZL34 PLAG1 transcripts contained significantly lower levels of exons E1 and E2 compared to controls. We did not detect significant variable splicing for any other gene with intronic insertions (Table S4 ). However, several other genes of hematopoietic interest, including HIF3A, demonstrated both changes in isoform abundance (Table S4 ) and overall upregulation( Figure 3E ). We next mined RNA-seq data for fusion transcripts. We detected fusions between vector and PLAG1 sequences in ZL34 nRBC and abundant hybrid forms containing vector sequences spliced to E3, before the translation start site, including isoforms with and without E4( Figure 5B ; Table S5 ), predicted to encode the two major isoforms of PLAG1 protein 35 . We also detected fusion EIF3E and NCAM2 transcripts( Figure S10 ; Table S5 ), however, EIF3E was not overall upregulated in ZL34( Figure S7 ). A subset of these hybrid transcripts were confirmed by RT-PCR(Figures 5B;S10). We did not detect hybrid transcripts for the other genes with intronic insertions nor any non-LV fusion transcripts.
Discussion
We describe the first case of lentiviral insertion-induced genotoxicity resulting in hematopoietic clonal expansion and a neoplastic phenotype in a large animal or human.
Following autologous transplantation of HSPC transduced with a barcoded LV containing the MSCV promoter-enhancer within the LTR, one macaque developed a fatal myeloproliferative/myelodysplastic syndrome linked to clonal expansion from a single transduced HSPC.
The development of leukemias in clinical gene therapy trials and in primate models utilizing murine g-retrovirus vectors(RV) to transduce HSPC stimulated a search for safer gene transfer systems [9] [10] [11] . Evidence implicated RV activating nearby cellular proto-oncogenes with strong viral enhancers, exacerbated by RV integration favoring transcription start sites(TSS) 13 . LV had endogenous enhancers removed, and were shown to have an integration pattern favoring gene bodies rather than promoters, hypothesized to be less likely to activate proto-oncogenes 36,37 . Genotoxicity models including in vitro immortalization of murine HSPC and acceleration of leukemia in tumorprone mice predicted significantly lower genotoxicity from LV versus RV, even when strong viral promoters derived from RV were inserted within LV backbones [38] [39] [40] [41] .
The majority of HSPC clinical gene therapy trials over the past decade have utilized LV to try and decrease the risk of genotoxicity and take advantage of increased efficiency of HSPC transduction associated with this vector class 1, 42 . Most trials have utilized or are utilizing LV with internal weak constitutive or lineage-specific promoters, although several trials for diseases requiring very high transgene expression, such as adrenoleukodystrophy, continue to employ LV with very strong internal viral promoter/enhancers.
In the majority of our barcoded macaques, including ZL34, we used a LV construct containing the MSCV viral promoter/enhancer inserted within the LTR. The original MSCV RV vector was derived from a mutant murine myeloproliferative sarcoma virus (MSPV) with high expression in hematopoietic cells, and the MSCV promoter/enhancer was later shown to drive consistent high stable transgene expression in human HSPC when included in LV vectors 43, 44 . In a previous study, we reported development of AML following transduction of macaque HSPC using an RV vector containing the MSCV promoter/enhancer 10 . However, in 6 macaques transplanted with HSPC transduced with the same LV barcoding vector containing the MSCV sequences, we have tracked over 65,000 individual clones for up to 5 years without clonal expansions. In addition, 3 macaques received HSPC transduced with a barcoded LV containing an internal EF1α promoter showed clonal patterns indistinguishable from the MSCV animals (Table S1 and 15 ).
Because RV promoter/enhancers included in LV vectors promote high constitutive transgene expression, two clinical trials for adrenoleukodystrophy have included a RV promoter/enhancer similar to MSCV, termed MND, in the LV to drive high expression of the transgene 4, 5, 45, 46 . In contrast to the vector utilized in ZL34, the adrenoleukodystrophy trial LV placed the RV promoter/enhancer internally, instead of within the LV LTR 4, 5, 45, 46 . Tumor-prone mouse models have suggested that an internal strong promoter/enhancer is less genotoxic than the same promoter/enhancer placed within the LV LTR 39 . Thus far, no clonal expansions or hematopoietic toxicity have been reported in the 23 patients enrolled in these trials, with many years of follow-up. Other clinical trials using LV containing endogenous or weaker constitutive promoters have reported polyclonal hematopoiesis for years post-transplantation 6,47-50 . However, a thalassemia patient developed a marked clonal expansion linked to insertion of an LV containing an internal erythroid-specific promoter, resulting in increased expression and aberrant splicing of HMGA2, without any associated abnormalities of hematopoiesis 8 .
Recently, persistence and massive clonal expansion of a CAR-T cell clone in a patient was linked to an LV insertion inactivating the epigenetic regulator TET2 14 .
The expanded neoplastic clone in our macaque had 9 insertions, with 4 out of the 9 insertions located within introns. We believe the most compelling candidate insertion driving the HSPC phenotype was within the gene encoding the zinc finger protein PLAG1. PLAG1 has been identified as a cooperating neoplastic "hit" via a mutagenesis screen in Cbfb-MYH11 murine leukemias and is upregulated in 20% of human AML 24 .
Recent studies have reported a role for PLAG1 in stimulating expression of Mushashi-2, a protein that stimulates HSPC expansion 30 , and in expanding engrafting HSPC ex vivo(Hope et al, ASH 2017). Detection of abundant aberrant splicing and LV-PLAG1 mRNA fusions corroborates previous reports of LV-associated aberrant splicing 8, 33, 34, 51, 52 . Of note, the LV-PLAG1 splicing abrogated expression of non-translated E1 and E2, while maintaining expression of exons 3, 4 and 5, encompassing all translated sequences. We detected transcripts both with and without E4, predicting translation of both the short and long isoforms of PLAG1 protein 26 . Functional differences between the two PLAG1 isoforms are poorly understood.
We observed upregulation of expression of known downstream targets of PLAG1 in ZL34 cells, most notably IGF2 and MSI2 30 . Imprinting-related downregulation of IGF2 at the IGF2/H19 locus maintains HSPC quiescence, with loss of imprinting resulting in murine HSPC proliferation, and exhaustion 53 . MSI2 encodes the Musashi-2 RNAbinding protein, which promotes the expansion of long-term repopulating HSCs 31 and regulates self-renewal 54 . Overexpression of PLAG1 in CD34+ cells has been reported to stimulate HSPC expansion ex vivo(Hope et al, ASH 2017). It is interesting to note that HMGA2 was downregulated in ZL34 hematopoietic cells compared to those from normal controls. HMGA2 is a transcription factor which functions as a critical upstream regulator of PLAG1 expression 32 . An LV insertion resulting in overexpression of HMGA2 was linked to the marked clonal expansion in an LV gene therapy trial noted above 8 and based on the HSPC expansion seen in our animal, it seems possible that dysregulation of PLAG1 and downstream targets may have contributed to the expansion, although to our knowledge, no aberrant hematologic phenotype developed in that patient. The downregulation of HMGA2 in ZL34 HSPC coincident with upregulation of PLAG1 and downstream targets suggests that HMGA2 may be involved in normal hematopoiesis, and regulated by feedback from downstream targets.
Although we suspect that genotoxicity linked to the PLAG1 insertion likely played a key role in ZL34's phenotype, we cannot rule out roles for other insertions. Given doses transplanted, HSPC with LV insertions in PLAG1 have almost certainly been delivered to our other macaques without development of abnormal clonal hematopoiesis. An insertion just downstream of KITLG resulted in upregulation of SCF, with a small increase in serum SCF. Cell-associated SCF protein was increased in HSPC also expressing the KIT receptor, suggesting autocrine signaling, previously shown for other cytokines to drive proliferation in hematopoietic cells 55 . We have administered pharmacologic doses of SCF to macaques and have not observed eosinophilia or release of nRBC into the circulation, thus overexpression of SCF was unlikely to be the sole driver of ZL34's aberrant hematopoiesis. However, it is of interest to note that production of fetal hemoglobin increases in baboons administered SCF 56 , and in human erythroid cultures supplemented with SCF 57 , suggesting dysregulation of SCF may have underlied elevated HbF in ZL34. Insertions upregulating expression or leading to aberrant splicing of NCAM2, ISOC1, or EIF3E seem less likely to be contributing to clonal expansion and the phentoype, given the lack of known roles for these genes in hematopoiesis or leukemogenesis. Expression of testin(TES) RNA was decreased, a gene with tumor suppressor activities, potentially via inhibition of cell migration and metastasis 58 . It is intriguing to speculate that loss of TES expression might have contributed to abnormal release of nRBC into the blood. The constraints of the primate model and our inability to derive immortalized lines from ZL34 precluded further direct investigations of the contribution of each specific insertion to the hematologic phenotype.
In conclusion, this fatal genotoxic clonal expansion adverse event linked to LV insertions is concerning. The implications of this event must be balanced against the encouraging safety and efficacy of LV HSPC gene therapy clinical trials in patients with life-threatening diseases. It is also important to note that the vector resulting in toxicity in our macaque model included a strong viral promoter/enhancer within the LTR, a design shown associated with increased genotoxicity in preclinical models, and not utilized in any clinical trial to date. However, we believe our findings imply that strong viral promoters should be avoided in LV whenever possible. In addition, approaches to decrease LV-related aberrant splicing should be pursued, given our evidence that upregulation of PLAG1 was driven by primarily by hybrid transcripts. Targeted gene gene editing approaches avoid semi-random vector insertion and have the potential to be a less genotoxic technology, though these approaches are in their infancy and may be associated with a different set of off-target genotoxicities 59-61 . Days post transplant Eosinophils (10^3)/uL Table S3 . , and a macaque recovering from malarial anemia (CA3K). Gating of BM CD45cells were used as an alternative marker for nRBCs in these studies, due to destruction of the CD71 epitope during permeabilization for intracellular staining. >85% of CD45-cells are nRBCs (Fig.S6C ). ZK19 is a non-transplanted normal monkey. (C) ZL34 and control BM samples (ZL08: non-transplanted, JD46 and ZL40: barcoded animals) stained via immunohistochemistry for PLAG1, SCF, and NCAM2. (D) Mean-centered gene expression levels for PLAG1, its putative upstream regulator HMGA2, and PLAG1 downstream targets IGF2, DLK1, and MSI2 in ZL34 and control samples. Expression levels are rlog values from DESeq2. 
Supplemental Methods
Cell purification and FACS analysis
PB and BM samples were separated into granulocyte and mononuclear cell fractions via centrifugation over lymphocyte separation medium (MP Biomedical) and stained with antibodies (Table S7) 
Vector integration site retrieval
Vector integration sites were identified retrieved as described 50 . Briefly, genomic DNA was sheared (Covaris) to an average size of 300-500bp, end repaired and dAtailed. T-Linkers (Oligoseq) were ligated to the resulting fragments. PCR was performed using one LTR-specific primer and one linker-specific primer followed by nested primers containing Illumina sequencing adaptors. The resulting library was sequenced on an Illumina MiSeq. Integration site junctions were trimmed with custom Perl scripts and mapped to rheMac8 using Blat.
Analysis of vector integration sites relative to known regulatory sequences
The locations of vector integration sites were compared to CTCF binding sites as determined by chromatin immunoprecipitation sequencing (ChIP-seq to compute overlaps between vector integration sites and ATAC-seq peaks.
Hemoglobin chain measurements
Whole blood cell pellets were lysed in 100 µL HPLC-grade water by pulsevortexing for 30 seconds (3X) followed by one cycle of freeze-thawing and centrifugation at 16,000Xg for 15 minutes. minutes at up to 75% and re-equilibrated for 10 minutes at 35%. The globin types were detected at 215nm and confirmed by an Agilent HPLC-6224 mass spectrometer equipped with an ESI interface and a time-of-flight (TOF) mass detector as previously described 67, 68 . 
Soluble SCF detection by using ELISA
Histologic and immunohistochemical analyses
BM biopsies were obtained from posterior iliac crests. Following fixation and decalcification, sections were prepared. Spleen samples were obtained at time of autopsy. Antibodies utilized for immunohistochemical staining are listed in Table S7 .
Analysis of differential usage of splice variants
We implemented a pipeline to detect fusion genes in parallel with computing differential usage of gene features and detects. In brief, STAR v 2.6.0c 63 
Data availability
All data and code used in this study (RNA-seq and barcode data) will be made available upon request from the corresponding authors. Figure 3 illustrates the significant dysregulation of only 5 of these genes (PLAG1, KITLG, NCAM2, ISOC1, and TES) when comparing nRBC plus HSPC samples in ZL34 and controls. Expression levels are rlog values from DESeq2. Figure S10 . EIF3E and NCAM2 hybrid transcript detection. Hybrid vector-gene transcripts were detected within ZL34 for Barcode 5 and its intronic host, EIF3E (A), as well as for Barcode 4 and its intronic host, NCAM2 (B). Subsets of the results were able to be confirmed by RT-PCR and Sanger sequencing. Table S1 . Transplant information and follow-up for all transplanted letivirally-barcoded macaques. Table S2 . Viral integration site retrieval in ZL34. Viral integration site retrieval (5' and 3'-based) in ZL34 nRBC DNA at 309 and 393 days post-transplant, and in granulocyte DNA at 96 days posttransplant. Green denotes the integration site recovered has been matched to one of the originally recovered barcodes and is concluded to arise from the single expanded clone in ZL34. Table S4 . Differentially spliced genes in ZL34. Differential expression of gene features (e.g. exons or exon junctions) obtained from the comparison of RNA-seq data from (i) four samples from ZL-34 (1 sample of nucleated erythrocytes from peripheral blood, 2 samples of nucleated erythrocytes from bone marrow and 1 sample of CD34+ cells obtained from bone marrow) and (ii) 4 samples from a wild type macaque (2 samples of nucleated erythrocytes obtained from bone marrow and 2 samples of CD34+ HSPCs obtained from BM). Differential expression of features was computed with our pipeline and a custom index for the combined macaque and lentiviral as described in the supplemental methods. Tab 1 is a gene level overview of features (e.g. exons or junctions) that are differentially expressed with an adjusted p-value of less than 0.05. The meanings of the columns is described in comments added to each column and also tabulated below. Tab 2 is a more detailed presentation of the results at the level of individual gene features. Again, the meanings of each of the columns is described in comments added to each column and also tabulated below. Columns on Tab The base mean normalized coverage counts for the locus across all conditions. Column 9 (geneWisePadj):
Supplemental Methods References
The gene-level p-value that one or more features belonging to this gene are differentially used. This value will be the same for all features belonging to the same gene. sample of CD34+ cells obtained from bone marrow using our pipeline as described in the supplemental methods). The first column tabulates the left break point which is located in the lentiviral insertion (LVI). The LVI act as a splice donor and five different (LVI) break points were observed in fusion genes with EIF3E; 3 of the same LVI breakpoints were also observed in fusions with PLAG1 and NCAM2; we highlight the fact that the other 2 breakpoints were not observed with rows with zero entries. The second column depicts the right break point. In each case these are starts of known exons. Columns 3 through 6 denote the fusion fragments per million as computed from our pipeline and described in the supplemental methods. Most of the fusion genes were confirmed by PCR as indicated in the 7th column of the table. As depicted in the 8th column two of the splice junctions were previously reported by Cesana et al 33 . 
